PP
DNTH icon

Paloma Partners’s Dianthus Therapeutics DNTH Stock Holding History

Paloma Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,214
Closed -$544K – 88
2025
Q2 		$544K Buy
+29,214
New +$548K 0.08% 89
2020
Q3 		– Sell
-697
Closed -$84K – 2162
2020
Q2 		$84K Buy
+697
New +$98.2K ﹤0.01% 1925

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paloma Partners's DNTH Position: Q3 2025 in Review

Paloma Partners sold out of Dianthus Therapeutics (DNTH) in Q3 2025, closing a stake of 29,214 shares — an estimated $544K sold.

Paloma Partners first reported a position in DNTH in Q2 2020 and held it in 2 quarters. The position peaked at $544K in Q2 2025. 140 funds tracked by Wall St. Rank hold DNTH as of Q3 2025.

  • Paloma Partners reported no remaining Dianthus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Paloma Partners sold 29,214 Dianthus Therapeutics shares in Q3 2025, an estimated $544K.
  • Paloma Partners first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 2 quarters.
  • Paloma Partners's Dianthus Therapeutics position peaked at $544K in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.